Sugi Predict

Sugi Predict / Compounds / SCHEMBL1254599

SCHEMBL1254599

SCHEMBL1254599

CCOC(=O)CC1CCCC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ LMNA P02545 1/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ POLB P06746 1/20 0.42
▸ CYP11B1 P15538 1/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ PTGS1 P23219 3/20 0.38
▸ PTGS2 P35354 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ MGAM O43451 1/20 0.38
▸ SI P14410 1/20 0.38
▸ MGAM2 Q2M2H8 1/20 0.38
▸ HSD17B1 P14061 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11241585 0.95 CYP2D6 (0.55) CYP2D6SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL534241 0.95 CYP2D6 (0.55) CYP2D6SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL10412651 0.93 CYP2D6 (0.54) CYP2D6SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL11082604 0.93 CYP2D6 (0.54) CYP2D6SMN1; SMN2NPC1RAB9ALMNA
Toluene SCHEMBL28301657 0.89 NPC1 (0.48) CYP2D6SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL6675357 0.83 NPC1 (0.55) CYP2D6SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL2565281 0.82 NPC1 (0.42) CYP2D6SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL10477344 0.81 RAB9A (0.49) CYP2D6SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL15011338 0.81 POLB (0.41) CYP2D6SMN1; SMN2KMT2APOLBALDH1A1
SCHEMBL28358461 0.81 CYP2D6 (0.42) CYP2D6SMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109809990-A A method of 2- oxocyclopentyl ethyl acetate is prepared by esterification 雷萌 2019-05-28 — — CN claimed
CN-105646209-A Synthesizing method of ethyl 2-oxocyclopentylacetate 苏州艾缇克药物化学有限公司 2016-06-08 — — CN claimed
CN-1823053-A 1,2, 4-trioxepanes as lactone precursors AKZO NOBEL NV (NL) 2006-08-23 — — CN claimed
EP-1646618-A1 1,2,4,-TRIOXEPANES AS PRECURSORS FOR LACTONES Akzo Nobel N.V. (NL) 2006-04-19 — — EP claimed
WO-2005014569-A1 1,2,4,-TRIOXEPANES AS PRECURSORS FOR LACTONES AKZO NOBEL N.V. (NL) 2005-02-17 — — WO claimed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
WO-2025106863-A1 LACTAM DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2025-05-22 — — WO disclosed
US-20250074874-A1 SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2025-03-06 — — US disclosed
US-12209072-B2 Cyclopentyl acids as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2025-01-28 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-4996223-A Substituted 1,2,3,4-tetrahydrocarbazoles as analgesics; side effect reduction THE VICTORIA UNIVERSITY OF MANCHESTER (GB) 1991-02-26 — — US disclosed
EP-0312539-A1 NEW ORGANIC COMPOUNDS HAVING OPIOID PROPERTIES THE VICTORIA UNIVERSITY OF MANCHESTER (GB) 1989-04-26 — — EP disclosed
WO-1988000193-A1 NEW ORGANIC COMPOUNDS HAVING OPIOID PROPERTIES THE VICTORIA UNIVERSITY OF MANCHESTER (GB) 1988-01-14 — — WO disclosed
US-4094896-A HYPOTENSIVE AGENTS, BACTERICIDES AND FUNGICIDES AMERICAN CYANAMID COMPANY (US) 1978-06-13 — — US disclosed
US-4054604-A MICROBIOCIDES, HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1977-10-18 — — US disclosed
US-4044043-A HYPERTENSIVE AGENTS, MICROBIOCIDES AMERICAN CYANAMID COMPANY (US) 1977-08-23 — — US disclosed
US-4006179-A HYPOTENSIVE AGENTS, MICROBIOCIDES AMERICAN CYANAMID COMPANY (US) 1977-02-01 — — US disclosed
US-3981868-A MICROBIOCIDES, HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1976-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP2D6 3599/4885SMN1; SMN2 2647/4885NPC1 3159/4885
US-12209072-B2 Cyclopentyl acids as LPA antagonists LPAR1, LPAR5, LPAR2 CYP2D6 2084/4885SMN1; SMN2 4240/4885NPC1 302/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP2D6 3599/4885SMN1; SMN2 2647/4885NPC1 3159/4885
US-20250074874-A1 SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS S1PR1, S1PR3, S1PR2 CYP2D6 3093/4885SMN1; SMN2 3344/4885NPC1 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.